To reveal more information about each member, please click on the + sign
Professor Paul Emery OBE
Professor Emery trained at Cambridge, Guy’s and Brompton. After completing his accreditation in rheumatology and general internal medicine (GIM), he was Head of Rheumatology at Walter & Eliza Hall Institute and Consultant at the Royal Melbourne Hospital in 1985. He returned to the University of Birmingham as a Senior Lecturer in 1987. Since 1995, he has been Versus Arthritis UK Professor of Rheumatology in Leeds and inaugural Director of the Leeds National Institute for Health Research (NIHR) Biomedical Research Centre from 2009 to present.
Professor Emery was President of European League Against Rheumatism (EULAR) 2009–2011. He was chair for the Executive Committee for Foundation for Research in Rheumatology (FOREUM), and is an American College of Rheumatology (ACR) Master. He has served on the editorial boards of all the major rheumatology journals. He was inaugural President of the International Extremity MRI Society (ISEMIR). He has been an NIHR Senior Investigator since 2008. He is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year award 1999; and the EULAR prize 2002 for outstanding contribution to rheumatology research. In 2012, he was awarded the Carol Nachman Prize. In 2018, he was awarded an OBE by the Queen for services to rheumatology.
Professor Emery’s research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, psoriatic disease and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He was instrumental in bringing sensitive imaging (MRI/US) into rheumatology practice. He established the concept of early intervention in inflammatory arthritis, with a model for early arthritis now adopted throughout the world. He is currently focusing on the prevention of autoimmune diseases with national programmes to identify patients in the pre-clinical phase. This prevention strategy is applied not only to inflammatory arthritis but to systemic lupus erythematosus, Sjogren’s syndrome, scleroderma and psoriatic disease. He has published >1100 peer-reviewed articles in this area, he has an h factor of >140.
Professor Alexander Bennett
Alexander Bennett is the Defence Professor of Rheumatology and Rehabilitation, has been a Consultant in Rheumatology and Rehabilitation at the Defence Medical Rehabilitation Centre, Stanford Hall since October 2008, the Head of the Academic Department of Military Rehabilitation since June 2011 and is the Royal Air Force Consultant Advisor in Rheumatology and Rehabilitation. He is an honorary Clinical Professor at Loughborough University and an honorary senior lecturer at Imperial College, London.
He is a Fellow of the Royal College of Physicians and a member of the British Society for Rheumatology, the Faculty of Sports and Exercise Medicine and the International Society of Assessment in Ankylosing Spondylitis (ASAS), is a member of The Assessment in Spondyloarthritis Society (ASAS) MRI working group and is the secretary to the British Society of Spondyloarthritis.
He was appointed Defence Professor of Rheumatology & Rehabilitation in March 2017 and oversees all research at the Academic Department of Military Rehabilitation, which focuses on musculoskeletal injury and disease and trauma rehabilitation and outcomes.
Professor Bennett has a keen interest in research, as well as clinical aspects of rheumatology and rehabilitation, and particularly in axial spondyloarthritis. He has published widely in rheumatology, in particular in the fields of early diagnosis and prognosis in seronegative inflammatory arthritis/spondylitis. He has lectured on many occasions at national, European and American rheumatology conferences.
Dr Antoni Chan
Antoni Chan is a Consultant Rheumatologist and physician at the Royal Berkshire Hospital, UK.
Dr Chan gained his Medicine qualification in 1997, with commendation from the University of Aberdeen, Scotland. He became a member of the Royal College of Physicians (RCP) in 2000 and went on to complete specialist rheumatology training in Oxford, UK.
He was awarded the Arthritis Research UK (ARUK) Clinical Research Fellowship from 2003 to 2006, when he completed his laboratory and clinical research into the immunology of rheumatic diseases. Later, he was awarded a PhD for his doctoral work. Dr Chan was the recipient of the 2018 National Ankylosing Spondylitis Society (NASS) Patients' Choice award for the best care provided by a Rheumatologist. He is currently a fellow of the RCP (London), member of the British Society of Immunology and examiner of the Member of the RCP (MRCP) examinations.
As well as being a primary investigator for clinical research studies, his clinical research interests include undifferentiated inflammatory arthritis, ankylosing spondylitis and rheumatoid arthritis.
Dr Laura Coates
Laura Coates is a National Institute for Health Research (NIHR) Clinician Scientist and Senior Clinical Research Fellow at Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK. She completed her rheumatology training and PhD in 2017 at the Leeds Institute of Rheumatology and Musculoskeletal Medicine, which is part of the University of Leeds.
Dr Coates is a member of the Steering Committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the British PsA Consortium (BritPACT). She is the first author on the 2015 GRAPPA treatment recommendations for psoriasis and psoriatic arthritis (PsA) and is also involved in the GRAPPA/OMERACT initiative to refine the core set of outcome measures for PsA. She is the first author of the Tight Control of Psoriatic Arthritis (TICOPA) study, the first study to address treating to target in PsA that improved clinical and patient reported outcomes. Dr Coates was awarded one of eight UK Scopus Young Investigator Awards in 2011 and a University of Leeds Women of Achievement Award in 2012.
Her clinical and research interests focus on PsA and spondyloarthritis, including early diagnosis of PsA, development of PsA-specific and validated outcome measures, optimal treatment pathways and strategies in PsA.
Dr Gurdeep Dulay
Gurdeep Dulay is a Consultant in Rheumatology and General (Internal) Medicine at Portsmouth Hospitals NHS Trust, having obtained his medical degree from the University of Southampton in 2006.
Dr Dulay has represented his colleagues at a national level for both the British Society of Rheumatology and the Royal College of Physicians (RCP). He has presented work at national and international levels and been selected to undertake roles in medical education and postgraduate examinations, including writing postgraduate exam questions for national and international use by the RCP (MRCP Practical Assessment of Clinical Examination Skills (PACES) examination).
His clinical and research interests focus on psoriatic arthritis, axial spondyloarthropathy connective tissue disease and ultrasound.
Dr Nicola Goodson
Nicola Goodson trained in Medicine at the University of Liverpool. She was awarded an honorary clinical research fellowship based at the Arthritis Research UK Epidemiology Unit in Manchester University, where she obtained a PhD in Epidemiology for her work exploring cardiovascular morbidity and mortality in patients with early inflammatory polyarthritis.
She was appointed to her current position of Senior Lecturer in Rheumatology at the University of Liverpool and Honorary Consultant Rheumatologist at Aintree University Hospital in 2004, and in 2005 she undertook a sabbatical post as visiting Professor in the Department of Pharmaco-Epidemiology, Brigham & Women’s Hospital. She leads the high cost rheumatology drug service at Liverpool University Hospitals NHS foundation Trust and is clinical lead for the spondyloarthopathy service. She has a leadership role for Integrated clinical academic training (ICAT) in Liverpool and is Athena Swan lead for ICAT.
Dr Goodson has published over 40 peer reviewed papers. Her clinical and research interests are focussed around epidemiology and pharmacoepidemiology of comorbidity complicating inflammatory rheumatic conditions.
Professor Philip Helliwell
Philip Helliwell is Professor of Clinical Rheumatology at the University of Leeds, UK, and Honorary Consultant Rheumatologist for the Leeds and Bradford Teaching Hospitals NHS Trust. Dr Helliwell qualified in Oxford in 1972 and worked initially in London before returning to work in his native Yorkshire in medical physics.
He is a member of the Assessment in Spondyloarthritis Society (ASAS) and co-founder and President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He established and led the CASPAR study for classification of psoriatic arthritis (PsA). He has worked with GRAPPA in developing single and composite outcome measures in PsA and completed the first treat to target strategy study (TICOPA) in early PsA.
Professor Helliwell is co-founder and co-lead for the Bradford (University) Diploma in Rheumatology and Musculoskeletal Medicine and is an active member of the Bradford and Airedale Musculoskeletal Alliance, a tier 2 service provided to GPs in the designated geographical area.
Professor Helliwell has published over 300 peer reviewed papers. Current and past research in PsA includes treatment paradigms, clinical features and classification of PsA and community-based studies of psoriasis and PsA.
Dr Pauline Ho
Pauline Ho is a Consultant Rheumatologist and Honorary Senior Lecturer at the University of Manchester, UK.
She graduated from the University of Wales College of Medicine in Cardiff in 1995 with an Honours degree. She also has an intercalated degree in Biochemistry (funded by the Medical Research Council [MRC]). She obtained her membership to the Royal College of Physicians in January 1998 and undertook specialist training in rheumatology in the North West region. During the training, she studied for an MSc in rheumatology. In addition, she obtained funding from the MRC to complete a PhD studying the genetics of psoriatic arthritis with the arc-Epidemiology Unit at the University of Manchester.
Her clinical interests are in rheumatology and pain management.
Dr Deepak Jadon
Deepak Jadon is a Consultant Rheumatologist, Director of the Rheumatology Research Unit, and lead for psoriatic arthritis (PsA) at Addenbrooke’s Hospital, Cambridge, UK. He graduated from the University of Wales College of Medicine in 2003, and then undertook clinical training in rheumatology and general internal medicine in Bath and Bristol, UK between 2007 and 2015. He completed his PhD thesis on ‘biomarkers of psoriatic arthritis phenotypes’ at the Royal National Hospital for Rheumatic Diseases, Bath in 2015.
Dr Jadon is a member of the Royal College of Physicians (London), the British Society for Rheumatology, the Royal Society of Medicine (London) and the Group for Research of Psoriasis and Psoriatic Arthritis (GRAPPA).
His research interests include genetic and serum biomarkers of PsA, ankylosing spondylitis (AS) and spondyloarthritis (SpA), in particular those that predict prognosis and developing psoriatic spondyloarthritis or arthritis mutilans. He has also researched the clinical and radiographic differences between PsA and AS, and juvenile- vs. adult-onset AS. As Director of the Rheumatology Research Unit, he leads on phase 2a to phase 4 clinical studies of novel therapeutic agents for PsA, AS, SpA and rheumatoid arthritis.
Dr Alison Kinder
Alison Kinder is Head of Service for Rheumatology at University Hospitals of Leicester NHS Trust.
She graduated from Nottingham University Medical School and went to work in Australia for a year to experience a different healthcare system. After travelling overland from Australia to the UK, she then undertook a rheumatology role in Liverpool. Dr Kinder completed Senior House Officer and Specialist Registrar jobs in Nottingham and Leicester and became a consultant in Leicester in 2006. In 2013, Dr Kinder took on her current role as Head of Service for Rheumatology in Leicester, which is a large tertiary centre that covers a population of 1.2 million. In this role, Dr Kinder has increased the number of consultants from 6 to 11 and the number of specialist nurses from 3 to 5, as well as introducing prescribing pharmacists and nurse specialists into the service. The centre has taken on a number of Clinical Research Network research trials, been commended as highest recruiter and been a pilot site for GIRFT (Getting It Right First Time rheumatology workstream).
Dr Kinder’s specialist interests include providing young adults with a specialised service and psoriatic arthritis.
Professor Bruce Kirkham
Bruce Kirkham is a Consultant Rheumatologist at Guy’s & St Thomas’ NHS Foundation Trust, London, and Professor of Translational Rheumatology, King's College London, UK. Professor Kirkham qualified as a doctor in New Zealand, then undertook his postgraduate rheumatology training at Guy’s Hospital, London.
In 2001, Professor Kirkham was Co-clinical Investigator of the first study of infliximab in psoriatic arthritis (PsA). He set up a dedicated service to optimise care of patients with rheumatoid arthritis and PsA, which received the British Society of Rheumatology inaugural Outstanding Best Practice Award in 2013. In 2016, his team was named by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) as one of seven international best practice centres. His translational research is focussed on IL-17/23 immunology and best practice in inflammatory arthritis.
Dr Helena Marzo-Ortega
Helena Marzo-Ortega is a Consultant Rheumatologist for the Leeds Teaching Hospitals NHS Trust and an Honorary Clinical Associate Professor at the University of Leeds, UK. She is the Clinical Lead of the Spondyloarthropathy service at the Section of Musculoskeletal Disease and the Clinical Lead for the musculoskeletal (MSK) Specialty Group of the West Yorkshire UK Clinical Research Network (UKCRN).
Dr Marzo-Ortega’s main areas of interest are within the field of early arthritis, undifferentiated arthritis and spondyloarthritis including psoriatic arthritis, with a special focus on the role of imaging biomarkers and biologic therapies.
Professor Dennis McGonagle
Dennis McGonagle is Professor of Investigative Rheumatology at the National Institute for Health Research (NIHR) funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust. He trained in medicine at University College Dublin and graduated in 1990. He trained in General Medicine and Rheumatology at St James’s University Teaching Hospital in Dublin and at the Leeds General Infirmary, UK.
Professor McGonagle has led the establishment of a new academic Dermato-Rheumatology group between the Universities of Leeds and Bradford. He has served on the Editorial Board of Arthritis & Rheumatism and was a member of the Scientific Committee of the European League Against Rheumatism (EULAR) and is now on the Editorial board of The Annals of the Rheumatic Diseases.
His major interests include the use of imaging to understand pathogenic mechanisms of arthritis in man, tissue microanatomy studies and laboratory studies into mechanisms of therapeutic responses to drugs. He has undertaken research into enthesopathy for 20 years.
Professor Robert Moots
Robert Moots is Professor of Rheumatology at the University of Liverpool, UK. Qualifying in Medicine with distinction in London, he earned his PhD in Immunology at the University of Oxford, UK, and subsequently moved to Harvard Medical School, Massachusetts, USA, to continue his research, before returning to the UK to establish a new academic rheumatology group in Liverpool.
He has published extensively, is active in international societies, committees and lectures all around the world. He advises the pharmaceutical industry globally, advises the UK National Institute for Health and Care Excellence (NICE), including devising national quality standards for rheumatoid arthritis, is a medical advisor to UK patient groups and has recently ended a successful term as Editor-in-Chief of Rheumatology. Clinical service remains an important part of Professor Moots’ work and his unit has recently been designated UK National Centre for Behçet’s disease.
Professor Moots’ research interests focus on clinical and laboratory aspects of inflammatory rheumatic diseases, in particular investigating the role of neutrophils in inflammation.
Dr Raj Sengupta
Raj Sengupta is a Consultant Rheumatologist and Lead for axial spondyloarthritis (axSpA) at the Royal National Hospital for Rheumatic Diseases, Bath, UK RNHRD. Dr Sengupta has established a cohort of over 1000 patients with axSpA.
He is a member of the British Society for Rheumatology (BSR) Spondyloarthritis Special Interest Group, the BSR axSpA Biologics Guidelines Committee and a member of ASAS (Assessment of Spondyloarthritis International Society). Dr Sengupta is a trustee and medical advisor for the National Ankylosing Spondylitis Society (NASS) and was one of the founding members of the British Society for Spondyloarthritis (BRITSpA). Dr Sengupta was the recipient of the 2016 NASS Patients’ Choice award for the best care provided by a Rheumatologist.
Dr Sengupta is the Principal Investigator in several national and international clinical trials focussed on axSpA, and has been an invited speaker on axSpA at a number of national and international meetings. He also has many peer-reviewed publications covering axSpA.